Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618813 · ClinicalTrials.gov registry record · NA
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
A NA study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT00618813 is a NA study that has completed, run by Children's Oncology Group. The registered enrollment target is 35 participants.
The verdict
NCT00618813, a NA study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
This clinical trial is studying the side effects of combination chemotherapy and to see how well they work in treating patients with newly diagnosed localized Ewing sarcoma family of tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different ways may kill more tumor cells.
Interventions
- DRUG etoposide
- DRUG ifosfamide
- DRUG doxorubicin hydrochloride
- OTHER radiation therapy
- OTHER therapeutic conventional surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618813
The ClinicalTrials.gov registry entry for NCT00618813 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which etoposide is the first listed.
NCT00618813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618813 about?
NCT00618813 is a clinical study titled "Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors". This clinical trial is studying the side effects of combination chemotherapy and to see how well they work in treating patients with newly diagnosed localized Ewing sarcoma family of tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the ce...
What is the current status of trial NCT00618813?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2008-03.
What interventions are being tested in trial NCT00618813?
The interventions under investigation include: etoposide (DRUG), ifosfamide (DRUG), doxorubicin hydrochloride (DRUG), radiation therapy (OTHER), therapeutic conventional surgery (OTHER).
Who is sponsoring clinical trial NCT00618813?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.